Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer

Company distances its CheckMate 227 CTLA-4/PD-1 combo study from AstraZeneca's doomed MYSTIC trial, noting big differences, but also makes it clear that its options are very open for monotherapy and chemo combos in first-line lung cancer.